Medina MGR, Rodríguez-Wong U

Idioma: Español
Referencias bibliográficas: 30
Paginas: 82-85
Archivo PDF: 24.5 Kb.

RESUMEN

Los anticuerpos monoclonales son agentes inmunosupresores que actúan selectivamente sobre los efectos del factor de necrosis tumoral alfa, por lo que están indicados en el tratamiento de aquellas enfermedades donde se requiere inhibir las vías de activación y los efectos inflamatorios mediados por esta citocina: enfermedad de Crohn, artritis reumatoide, psoriasis, esclerosis múltiple, espondiloartrosis, neuritis óptica, polineuropatía, síndrome de Guillain-Barré.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Stigbrand T, Anistom KR, Sundstrom B, Makiya R, Stendahl U. Alternative technologies to generate monoclonal antibodies. Acta Oncol 1993; 32: 841-4.

2. Vicenti F, Nasham B, Light S. Daclizumab outcome of phase III trials and mechanism of action double therapy and the triple therapy study groups. Transplant Proc 1998; 30: 2125-8.

3. Maini RN. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate. Lancet 1999; 354: 1932-9.

4. Harrim NG. Summary of clinical trials in rheumatoid arthritis usinf infliximab, an anti-TNF alpha treatment. Ann Rheum Dis 1999; 58: 161-4.

5. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn’s disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc 1998; 30: 4126-7.

6. Arend WP, Dayer JM. Inhibition of the production of interleukin 1 and tumor necrosis factor alfa in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-60.

7. Van Dullemen HM, Van Deventer SJ. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.

8. McCabe RP, Woody J, Van Deventer SJ. A multicenter trial of cA2 anti TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology 1996; 110: A962.

9. Present DH. Infliximab for the treatment of fistulas in patients with Cronh’s disease. N Engl J Med 1999; 340: 1398-1405.

10. Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999; 116: 22-8.

11. Ricart E, Panaccione R, Loftus EU, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-9.

12. Schreiber S, Campieri M, Colomberl JF, Van Deventer SJ, Feagan B, Fedorak R. Use of anti-tumor necrosis factor agents in inflammatory bowel disease. Int J Colorrectal Dis 2001; 16: 1-11.

13. Cohen RD, Papalia J, Hanauer SB. Infliximab in steroid-sparing in luminal Crohn’s disease. Gastroenterology 2001; 120.

14. Cohen RD, Larson LR, Roth JM. The cost of hospitalization on Crohn’s disease. Am J Gastroenterol 2000; 95: 524-30.

15. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn’s disease recurrence. Am J Gastroenterol 2000; 95: 1139-46.

16. Van Assehe G, Vanbeekevoort D, Bielen D. MRI imaging of the effects of infliximab in perianal fistulizing Crohn’s disease. Gastroenterology 2001; 120: A68.

17. Hong JJ, Merel NH, Hanauer SB. Treatment of pyoderma gangrenosum complicating Crohn’s disease with infliximab. Gastroenterology 2001; 120: A621.

18. Hyans JJ, Morkowitz J, Wyelie R. Use in infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000; 137: 192-6.

19. Khan S, Henderson WA, Kocoshis SA. The use of infliximab in pediatric Crohn’s disease. Gastroenterology 2001; 120: A210.

20. Rodríguez-Wong U. Enfermedad de Crohn. En: Peláez M, Sánchez-Moret R. Ano, recto y colon. JGH Editores 2000; p. 283-7.

21. Van Oosten BW, Barkhof F, Truyen L. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531.

22. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimetric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropaty an open pilot study. Am Rheum Dis 2000; 59: 428-33.

23. Fredriksson T, Peterson U. Severe psoriasis-oral therapy with a new retinoid. Dermatológica 1978; 157: 238.

24. Lohner ME, Krueger JG, Gottlieb A. Clinical trials of a fully human anti-IL8 antibody for the treatment of psoriasis. Br J Dermatol 1999; 141: 989.

25. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumor necrosis factor – alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.

26. Ellis CN, Krueger GC, Haney JI, Benett DV, Magilavy DV. Safety and efficacy of retreatment with alefacept in chronic plaque psoriasis. Am Acad Dermatol march 2, 2001.

27. Bouza E. Prevención de infecciones concomitantes al tratamiento anti-TNF. Rev Esp Reumatol 2001; 28: 84-5.

28. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schweterman WD. Tuberculosis associated with infliximab, a TNF-alpha neutrolizing agent. N Engl J Med 2001; 345: 1098- 104.

29. Furst D, Yocum D, Han C. Clinical benefits of infliximab + methotrexate treatment for patients with rheumatoid arthritis who were no responders by ACR criteria. Arthritis Rheum 2001; 44: 80-168.

30. Chaudhari U, Romeno P, Muecahy LD, Doodey LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis a randomised trial. Lancet 2001; 357: 1842-7.